Purchase this article with an account.
Alan L Robin, Ryuji Ueno; 24-hour diurnal intraocular pressure (IOP) evaluation in eyes with POAG or ocular hypertension treated with unoprostone isopropyl as measured in both the sitting and supine position. Invest. Ophthalmol. Vis. Sci. 2014;55(13):551.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To assess the 24-hour IOP lowering effect of unoprostone isopropyl ophthalmic solution (UIOS) 0.15% dosed BID.
We enrolled 10 subjects with either POAG or ocular hypertension who had untreated IOPs ≥ 23 mm Hg and <32 mm Hg in at least one eye. Technicians administered one drop of UIOS 0.15% at 6 am and 10 pm daily for three days. While the patient was in the sitting position, IOP was measured using Goldmann tonometry; at the same time points, a Perkins tonometer was used to measure IOP with the patient supine. We measured IOP in both the supine and seated positions at Baseline and on Day 3 at the following time points: 0.75, 2, 4, 6, 10, 14, 18, and 22 hours after the 6 am dose.
The mean age of the subjects was 70.5 years. On Day 3, the mean change in 24-hour diurnal IOP from Baseline in the sitting position was 4.7±1.0 mm Hg (p<0.001). Overall, after three days of BID dosing, IOP reduction measured in the sitting position appears uniform and relatively flat over 24-hours. Mean change in nighttime IOP, assessed in the sitting position after the second daily-dose, is also statistically significantly lower post-treatment versus baseline (p<0.001). On Day 3, the mean change in 24-hour diurnal IOP from Baseline in the supine position was 4.2±0.8 mm Hg (p<0.001). Overall, after three days of dosing twice daily, IOP reduction measured in the supine position appears relatively flat over 24-hours. Mean change in nighttime IOP, assessed in the supine position after the second daily-dose, is also statistically significantly lower post-treatment versus baseline (p<0.001).
In this study, after three days of dosing, the 24-hour IOP curves of patients treated with unoprostone isopropyl 0.15% ophthalmic solution appear to be relatively flat and suggest around the clock efficacy with BID dosing. The IOP reduction was greater during the day than at night.
This PDF is available to Subscribers Only